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A  replication-deﬁcient  chimpanzee  adenovirus  expressing  Ag85A  (ChAdOx1.85A)  was assessed,  both
alone  and  in  combination  with  modiﬁed  vaccinia  Ankara  also  expressing  Ag85A  (MVA85A),  for  its
immunogenicity  and  protective  efﬁcacy  against  a Mycobacterium  tuberculosis  (M.tb)  challenge  in  mice.
Naïve  and  BCG-primed  mice  were  vaccinated  or boosted  with  ChAdOx1.85A  and  MVA85A  in different
combinations.  Although  intranasally  administered  ChAdOx1.85A  induced  strong  immune  responses  in
the lungs,  it failed  to consistently  protect  against  aerosol  M.tb  challenge.  In contrast,  ChAdOx1.85A  fol-
lowed  by MVA85A  administered  either  mucosally  or systemically,  induced  strong  immune  responsesuberculosis
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and  was  able  to  improve  the  protective  efﬁcacy  of  BCG.  This  vaccination  regime  has  consistently  shown
superior  protection  over  BCG  alone  and  should  be evaluated  further.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).mmunogenicity
. Introduction
Tuberculosis is a global health problem, with an estimated 9
illion new cases and 1.5 million deaths in 2013 [1]. BCG is the
nly available vaccine, and although protective against dissemi-
ated forms of childhood disease, it is not consistently protective
gainst adult pulmonary TB [2].
Vaccine development efforts are focused on either replacing BCG
live vaccines) or identifying ‘BCG boosting’ vaccines to improve
rotective immunity [3]. There two live vaccines currently in
linical trials, a recombinant BCG (rBCG VPM1002) [4] and a dou-
le deletion mutant of M.tb (MTBVAC) [5]. Subunit vaccines are
dministered after BCG and focus immunity to a single or a few
mmunodominant antigens. Subunit vaccine antigens are delivered
s either adjuvanted protein [6–9] or in viral vectors. There are cur-
ently seven subunit candidates being evaluated in clinical trials
10].
∗ Corresponding author at: The Jenner Institute, University of Oxford, Old Road
ampus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
el.: +44 1865 617606.
E-mail address: helen.mcshane@ndm.ox.ac.uk (H. McShane).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.017
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uRecombinant viral vectors represent a highly potent antigen
delivery system and several are currently being evaluated in TB
vaccine trials. The most advanced are the replication-deﬁcient
modiﬁed Vaccinia virus Ankara expressing Ag85A; MVA85A [11],
and human adenovirus, AdHu35 expressing Ag85A, Ag85B and
TB10.4; Aeras402 [12]. In addition, human adenovirus type 5
expressing Ag85A; AdHu5.85A, is at earlier stages of clinical testing
and completed a phase I study [13].
As TB is primarily initiated by the inhalation of aerosol droplets
containing Mycobacterium tuberculosis (M.tb) establishing an infec-
tion in the lung, a vaccine that induces a local lung immune
response could be advantageous. Induction of lung immune
responses by vaccination could potentially prevent the estab-
lishment of infection [14]. AdHu5.85A and MVA85A have both
been shown to be more protective when administered by the
intranasal compared to the systemic route in mice [15,16]. In addi-
tion, MVA85A administered by aerosol in BCG-vaccinated healthy
adults, was  well tolerated and induced strong mucosal and systemic
immune responses [17].In this pre-clinical study we  have used a replication-deﬁcient
chimpanzee adenovirus vector developed in Oxford (ChAdOx1)
[18]. Unlike human adenoviral vectors, chimpanzee adenoviral vec-
tors are not affected by pre-existing anti-vector immunity caused
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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y previous vector exposure [19,20]. This pre-existing immunity
ould reduce potency when the vaccine is administered in the
uman population [21,22].
MVA85A induces primarily CD4+ T cell responses [17,23] and
ecombinant adenoviral vectors induce primarily CD8+ T cell
esponses [24]. We  used ChAdOx1, modiﬁed to express 85A, ChA-
Ox1.85A, alone and in combination with MVA85A to optimise both
mmunogenicity and protective efﬁcacy.
. Materials and methods
.1. Vaccinations
Six to eight week old female Balb/c mice were purchased from
arlan, UK. All procedures were performed in accordance with the
K Animals (Scientiﬁc Procedures) Act 1986 under project licence
umber 30/2889 granted by the UK Home Ofﬁce.
Development of E1–E3 deleted replication deﬁcient AdHu5 and
hAdOx1 [18] to express codon-optimised Ag85A antigen from
ycobacterium tuberculosis has been previously described [18,25].
ice were vaccinated with a dose of 1 × 108 infectious units (ifu)
f ChAdOx1.85A and/or 5 × 106 plaque forming units (pfu) of
VA85A. Vaccinations were performed via the intradermal (i.d.)
r intranasal (i.n.) route, in a ﬁnal volume of 50 l.
BCG Pasteur was grown in-house in 7H9 Broth (BD, UK) con-
aining 0.05% Tween 80. Mice were vaccinated with 4 × 105 colony
orming units (CFU)/dose via the i.d. route.
.2. Challenge experiments
Mice were challenged using a Biaera AeroMP-controlled neb-
liser (Biera technologies; Hagerstown, USA) contained in a
iosafety level 3 TCOL isolator. Animals were loaded in nose-only
estrainers and exposed to aerosolised M.tb Erdman K01 (TMC107)
BEI resources; Manassas USA), prepared at 1 × 106 CFU/ml in the
ebuliser. The programme was run for 10 min  (plus 5 min  purge),
irﬂow 12 L/min, and pressure 20 psig. Mice were infected with
0–100 CFU, veriﬁed 24 h after challenge in two mice/experiment.
.3. Quantiﬁcation of CFU
Lungs and spleens of infected animals were harvested four
eeks after challenge. Organs were homogenised in re-inforced
ubes with ceramic beads containing 1 ml  PBS using Precellys
4 (Stretton Scientiﬁc, UK). Homogenised organs were diluted
n PBS and dilutions were plated in Middlebrook 7H10 plates
Sigma–Aldrich), containing OADC (BD Diagnostic Systems). Plates
ere incubated at 37 ◦C and counted three weeks later.
.4. Flow cytometry
Cells were extracted from the bronchoalveolar lavage (BAL)
uid, lung and spleen. BAL ﬂuid was obtained by three succes-
ive lung lavages with 0.5 ml  of 10 mM EDTA/PBS (Sigma). Lungs
ere perfused with PBS, chopped into small pieces, and digested
n DNase/collagenase (Sigma).
Cells were stimulated with 2 g/ml of each Ag85A peptide in a
ool of 66 peptides spanning the whole sequence (or media only
or unstimulated controls) and incubated for 2 h at 37 ◦C. Golgi plug
1 l/ml) (BD Biosciences) was added in each well and incubated for
 further 4 h followed by incubation overnight at 4 ◦C. The following
ay intracellular staining was performed.Initially, cells were stained for 10 min  with live/dead ﬁxable
ead cell stain (Invitrogen, UK) followed by surface staining with
nti-CD45R/B220, TCR, TCR, CD4 and CD8 (eBioscience). Fol-
owing permeabilisation using CytoFix/CytoPerm (BD Biosciences),3 (2015) 6800–6808 6801
cells were stained intracellularly with anti-IFN-, TNF-, IL-2 and
IL-17 (eBioscience). Samples were run on an LSR II ﬂow cytometer
and the data was analysed using FlowJo (TreeStar Inc, Ashland, US)
and Spice 5.3 (NIAID, US).
2.5. Statistical analyses and presentation
Statistical analysis was  conducted and graphs were generated
using GraphPad Prism 5. Analysis of two  data sets was performed
using Mann–Whitney or Kruskal–Wallis (non-parametric) or one-
way Anova followed by post hoc tests for comparing three or more
groups.
3. Results
3.1. Construction of ChAdOx1 expressing Ag85A and in vivo
assessment
A replication-deﬁcient chimpanzee adenovirus previously
developed in Oxford was  modiﬁed to express Ag85A [25]. As mice
have no pre-existing immunity to chimpanzee adenoviruses [26],
they were used to assess ChAdOx1.85A vaccine potency. After
a single intranasal immunisation with ChAdOx1.85A, lungs and
spleens were harvested four weeks later to evaluate antigen-
speciﬁc immune responses (Fig. 1A). In the lungs, ChAdOx1.85A
induced a signiﬁcant frequency of Ag85A-speciﬁc CD8+ T cells
secreting IFN compared to naïve mice (p < 0.05) and higher TNF
and IL17 compared to both naïve and BCG-vaccinated groups
(p < 0.05) (Fig. 1B). The percentages of cytokine-secreting CD4+ cells
induced were much lower, with only TNF and IL2 signiﬁcantly
higher in the vaccinated compared to naïve and BCG control group
(p < 0.05) (Fig. 1C). In the spleen, ChAdOx1.85A induced systemic
CD8+ cells secreting IFN, TNF and IL2 (Fig. 1D). CD4+ cells secret-
ing cytokines were very low (data not shown).
Four weeks after ChAdOx1.85A administration, mice were chal-
lenged with M.tb via the aerosol route and harvested four weeks
later for lung and spleen bacterial enumeration (Fig. 1A). BCG-
vaccinated animals had signiﬁcantly lower bacterial load compared
to unvaccinated mice (reduced by 1.46 log10 in lung, p < 0.001 and
1.57 log10 in spleen, p < 0.001) whereas ChAdOx1.85A only slightly
decreased the bacterial load of vaccinated compared to unvacci-
nated mice in the lung (0.32 log10, p = 0.047,) and spleen (0.2 log10,
p = 0.08) (Fig. 1E and F).
3.2. Boosting ChAdOx1.85A with MVA85A, optimising the time
interval
Since ChAdOx1.85A induced strong CD8+ T cell responses we
decided to use MVA85A, a strong inducer of CD4+ responses, as a
booster vaccine. To identify the optimal time interval between the
two vaccinations, mice were vaccinated i.n. with ChAdOx.85A and
boosted i.n. with MVA85A 2, 4 or 8 weeks later. One week after
the MVA85A vaccination, BAL, lung and spleen were collected from
each mouse to measure Th1 immune responses (Fig. 2A).
In the lungs, there was a signiﬁcantly higher number of CD4+
IFN producing cells in the 2 compared to the 8 week interval
(p < 0.05) (Fig. 2B). CD8+ responses were signiﬁcantly higher in the
2 week compared to the 8 week interval for IFN (p < 0.01), TNF
(p < 0.01) and IL2 (p < 0.01) (Fig. 2C). The populations of cytokine-
secreting cells were mainly single or double cytokine producers for
both CD4+ and CD8+ T cells (Fig. 2D and E). There were no differ-
ences in the number of cytokine secreting CD4+ or CD8+ cells in the
BAL between groups (Fig. 2F and G), whereas spleen responses were
lower than the BAL and lung responses, with the 4 week interval
inducing stronger CD8+ IFN responses (data not shown).
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Fig. 1. Assessing immunogenicity and protective potential of intranasally administered ChAdOx1.85A. (A) Experimental schema. (B) Balb/c mice were immunised i.n. with
1  × 108 ifu of ChAdOx1.85A and harvested four weeks later. Percentage of CD8+ and (C) CD4+ cells secreting IFN, TNF, IL2 and IL17 by lung cells. (D) Spleen CD8+ cytokine
responses. (E) Lung and (F) spleen bacterial load after aerosol M.tb infection four weeks after the last immunisation (6 weeks after BCG). *p < 0.05, **p < 0.01.
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Fig. 2. Optimisation of the time interval between intranasal ChAdOx1.85A and intranasal MVA85A. Lung and BAL data presented. (A) Experimental schema. Absolute numbers
of  lung CD4+ cells (B) and CD8+ cells (C) secreting different cytokines at two, four or eight week intervals between the two  vaccinations. Cytokine responses were measured
one  week after the MVA85A vaccination. (D) Pie chart and bar chart showing the polyfunctionality of the CD4+ cells. Bar chart: blue dots represent 2, red dots and green dots
the  8 week interval. (E) Pie chart and bar chart showing the polyfunctionality of the CD8 cells. (F) Absolute numbers of BAL CD4+ and (G) CD8+ T cell populations secreting
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oifferent cytokines one week after MVA85A vaccinations.
Based on the above data we decided to proceed with the 4 week
nterval between ChAdOx.85A and MVA85A.
.3.1. Optimisation of vaccination regime: immunogenicity
tudies
We then optimised a vaccination regime based on the two
iral vectors. Balb/c mice were either homologously or heterol-
gously boosted with ChAdOx1.85A (C) or MVA85A (M)  via thei.n. route. Three control groups ChAdOx1.85A i.n. alone, MVA85A
i.n. alone and BCG i.d. alone were included. Four weeks after
the last immunisation, lung and spleen responses were evalu-
ated using ICS assay (Fig. 3A). All regimes were able to induce
CD4+ and CD8+ T cells in the lungs. The M–C regimen was opti-
mal  at inducing CD4+ IFN and TNF and the C–C and C–M
regimen was optimal for the induction of CD8+ IFN and TNF
(Fig. 3B and C for IFN and supplementary Figure 1A and B for
6804 E. Stylianou et al. / Vaccine 33 (2015) 6800–6808
Fig. 3. Optimisation of the vaccination regime with homologous or heterologous prime boost vaccinations. (A) Experimental schema. (B and C) Lung CD4+ and CD8+ IFN
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0ecreting T cells detected in the lungs of mice four weeks after the last vaccination.
accination. (F) TCR IL17 secreting T cells in the lungs of vaccinated animals.
ll cytokines). No vaccine regime was able to induce strong CD4+
esponses in the spleen. C alone induced the strongest systemic
D8+ IFN and TNF responses; C–M and C–C also induced good
D8+ responses (Fig. 3D and E for IFN and supplementary Fig-
re 1C and D for all cytokines). Mice that received ChAdOx1.85A
C–M, C–C and C) all had TCR IL17 responses in the lung
Fig. 3F).
Supplementary Figure 1 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2015.10.
17. E) Spleen CD4+ and CD8+ IFN secreting T cells detected four weeks after the last
3.3.2. Optimisation of vaccine regime: protection studies
To evaluate the protective efﬁcacy of different vaccination
regimes, two duplicate challenge experiments were set up. In one
experiment Balb/c mice received ChAdOx1.85A i.n. and MVA85A
i.d. 4 weeks later (with and without BCG prime); and in the sec-
ond experiment the MVA85A boost was administered i.n. with
the same interval between vaccinations. Mice were challenged
with aerosolised M.tb four weeks after the last immunisation and
lung and spleen harvested four weeks later for CFU enumeration
(Fig. 4A).
E. Stylianou et al. / Vaccine 33 (2015) 6800–6808 6805
Fig. 4. Assessing the protective potential of different vaccine combinations administered alone or as a boost to BCG. (A) Experimental schema. (B) Lung CFU data from mice
f i.n. an
e  route
C
p
c
(our  weeks after M.tb Erdman aerosol challenge. ChAdOx1.85A was administered 
xperiment where both ChAdOx1.85A and MVA85A were administered via the i.n.
FU  value of each group.In the ﬁrst experiment (MVA85A administered i.d.) all the BCG-
rimed groups had signiﬁcantly lower bacterial load in the lungs
ompared to naïve mice and to mice that were not BCG primed
p < 0.001) (Fig. 4B). The B–C–M vaccinated mice had signiﬁcantlyd MVA85A i.d. (C) Spleen CFU data. (D) Lung CFU data from a separate challenge
. (E) Spleen CFU data. Each symbol represents one animal and the line the medianlower lung CFU than all the other BCG primed groups (p < 0.01) apart
from B–M–C (which was  not signiﬁcantly better when compared
to BCG). In the spleen, all groups that were primed with BCG had
lower CFU compared to naïve and non-BCG primed animals but
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one of the groups had lower bacteria compared to the BCG group
Fig. 4C).
When the experiment was repeated with MVA85A administered
.n.,  C–M, M–C  and C vaccinated mice had lower bacteria in the
ungs (p < 0.05) when compared to unvaccinated mice but only C–M
accination signiﬁcantly reduced the CFU in the spleen (p < 0.05);
CG-primed mice had signiﬁcantly lower load in both the lung and
pleen if they were boosted with C–M (B–C–M group) (p < 0.05)
Fig. 4D and E).
.4. Immunogenicity and protective efﬁcacy of the most
romising vaccination regimes
To directly compare the two most protective regimes, mice were
accinated with either B–C–M (M administered i.d.)  or B–C–M (M
dministered i.n.). Control groups included BCG alone or BCG fol-
owed by C. Protective efﬁcacy and immunogenicity was assessed
Fig. 5A).
The BCG-vaccinated group had signiﬁcantly lower bacterial
ounts compared to the naïve control group (p < 0.0001). In addi-
ion, C–Mi.d. signiﬁcantly improved the protective efﬁcacy of BCG
p = 0.05 in the lungs and p = 0.002 in spleen) whereas C–Mi.n.
pproached signiﬁcance in the lung and was signiﬁcant in the
pleen (p = 0.07 lung, p = 0.05 spleen) (Fig. 5B and C).
In a parallel immunogenicity experiment, Ag85A speciﬁc CD4
nd CD8 cytokine responses were measured in lungs and spleen,
our weeks after the last immunisation. ICS was used to quantify
nd compare the percentage of cytokine secreting CD4+ and CD8+
ells between groups. All BCG boosting vaccines induced stronger
D8+ than CD4+ T cells in both the lung (Fig. 5D and E) and spleen
Fig. 5H and I). BCG followed by ChAdOx1.85A was signiﬁcantly bet-
er at inducing IFN CD8+ cells in the lung when compared to naïve
nd BCG-vaccinated mice. A further boost with MVA85A failed to
nhance IFN production but i.d. MVA85A enhanced both TNF and
L2 responses. Boosting with ChAdOx1.85A and MVA85A increased
he double cytokine secreting CD4+ and CD8+ cells in the lungs
Fig. 5F and G). In the spleen, BCG-C–M i.d. induced the strongest
D8+ T cell response (Fig. 5I).
. Discussion
BCG is not effective against pulmonary TB, and subunit vaccines
esigned to boost its immunity and protective efﬁcacy are required.
ne vaccination approach is the use of replication-deﬁcient viral
ectors. These are very immunogenic and have a good safety record
s evidenced by a number of clinical trials against TB and a number
f other infectious diseases.
A single intranasal immunisation with ChAdOx1.85A, alone or as
 boost to BCG was highly immunogenic, inducing strong immune
esponses in the lungs and spleen. However, it resulted in no or
mall reduction in the bacterial load of vaccinated animals (Figs. 1
nd 4B–E). This absence of protection is in contrast to the intranasal
dministration of human adenovirus expressing the same antigen
15,27]. In mice AdHu5.85A has previously shown superior CD8+
mmunogenicity to ChAdOx1.85A, when administered intramuscu-
arly (only in high doses) [25]. In contrast, there was no difference
n protective efﬁcacy when we directly compared i.n. vaccination
ith our AdHu5.85A versus ChAdOx1.85A, followed by aerosol M.tb
hallenge (supplementary data Figure 2). The reason for this dis-
repancy is not clear but a possible explanation is that our infection
odel is more stringent. An infection with approximately 8 CFU,
easured 24 h post infection, resulted in 106 CFU in the lungs of
nfected mice at 4 weeks post infection and a dose of 800 CFU at
4 h post infection (supplementary data Figure 3A) lead to 109 CFU
n the lungs and mice succumbing to disease at day 24, 4 days before3 (2015) 6800–6808
the scheduled 4 week time point (supplementary data Figure 3B).
In contrast, when we  compare this to previously published data
using aerosol challenge, the same high challenge dose (880 CFU)
was not as virulent and resulted in a 106 CFU lung load, 4 weeks post
infection [28]. This suggests that our challenge application is partic-
ularly efﬁcient, generating small particles, 1–2 m (which then dry
down and become smaller), which can disseminate more efﬁciently
throughout and deep in the lungs [29]. Particle size and deposition
have been shown to have an effect on pathogenicity of an organism
[30]. This system is perhaps more similar to more stringent animal
species e.g. the guinea pig. When AdHu5.Ag85A was  used to boost
BCG-vaccinated guinea pigs, there was  no reduction in the bacterial
load compared to BCG-vaccinated animals [31].
Supplementary Figures 2 and 3 related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2015.10.017.
One signiﬁcant limitation of homologous prime-boost vacci-
nation regimens with the same viral vector is the induction of
anti-vector immunity induced after the primary vaccination. In
this study, mucosal homologous boosting of both ChAdOx1.85A
and MVA85A (Fig. 3) did not result in improvement in the lung
immune responses compared to a single vaccination, in agreement
with published data [32]. For this reason, heterologous prime-
boost immunisations with viral vectors are more promising. A
simian adenoviral vector, ChAd63, expressing malaria antigens,
followed by MVA  expressing the same malaria antigens, induced
strong immune responses that were higher than those induced by
one vector alone in clinical trials [33,34]. Surprisingly, boosting
ChAdOx1.85A with MVA85A did not induce stronger IFN when
compared to ChAdOx1.85A followed by ChAdOx1.85A or to ChA-
dOx1.85A alone (the median response was higher for the ﬁrst
two), whereas MVA85A followed by ChAdOx1.85A was better than
MVA85A followed by MVA85A (Fig. 3). Even though the level of
immune response was  similar between those groups it is possible
that the breadth of the immune response differs and this is worth
investigating further [34]. When C–M and M–C  were administered
i.n. (Fig. 4D) they were able reduce the bacterial load compared
to unvaccinated mice, however only the C–M regimen was able to
signiﬁcantly improve BCG efﬁcacy (Figs. 4B, D and E and 5B and C),
whichever the route of MVA85A. A possible reason for this efﬁcacy
could be the ability of C–M to induce central memory responses
which are not induced by BCG vaccination and might be needed for
durable protection [35,36].
B–C–Mi.n. and B–C–Mi.d. were directly compared in a chal-
lenge experiment, only B–C–Mi.d. signiﬁcantly improved BCG;
although the B–C–Mi.n. and B–C–Mi.d. were not signiﬁcantly differ-
ent (Fig. 5B and C). A likely explanation for the absence of protection
is that the slightly higher BCG protective efﬁcacy obtained in the
repeat experiment, which approached two  log 10 CFU, improve-
ment compared to naïve mice minimised the potential to observe
a further improvement in efﬁcacy by additional vaccinations.
Although the immune responses measured in these experi-
ments did not correlate with protective efﬁcacy, further work will
aim to identify potential correlates of protection that are unique
to the B–C–M regime. Further experiments, will address the abil-
ity of B–C–M to induce antigen speciﬁc memory responses and to
provide durable protection when mice are challenged much later
after vaccination. In addition, the distribution of antigen-speciﬁc T
cells in different lung compartments will be further explored [37].
ChAdOx1 expressing inﬂuenza A antigens was  safe and
immunogenic in clinical trials [38] and ChAdOx1.85A, currently
being evaluated in a phase I ﬁrst-time-in-man study is also showing
good safety and immunogenicity (McShane, personal communi-
cation), making this a promising vaccine candidate. This study
suggests that a further boost with MVA85A could potentially
improve its immunogenicity and its protective efﬁcacy. In the
E. Stylianou et al. / Vaccine 33 (2015) 6800–6808 6807
Fig. 5. Repetition of efﬁcacy and immunogenicity of the most promising regimes. (A) Experimental schema. (B) Mice challenged with aerosol M.tb Erdman four weeks after
the  last vaccination. Each symbol represents the lung bacterial load of one animal and the line the median of each group. (C) Spleen CFU data. Immunogenicity was  measured
four  weeks after the last vaccination and just before challenge. ICS was performed on lung samples. Each different colour bar represents the median value of one cytokine
and  the bar the range of each group. (D) Results from CD4+ and (E) CD8+ T cells. (F) Polyfunctionality of CD4+ T cells, (G) polyfunctionality of CD8+ T cells. Red colour on pie
chart:  IFN, TNF and IL2 secreting cells, blue: double, green: single cytokine secreting cells. (H) Percentage of CD4+ and (I) CD8+ T cells secreting cytokines in the spleen.
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alaria ﬁeld, in a clinical challenge study, heterologous prime boost
ith ChAd63 followed by MVA, both expressing METRAP, conferred
1% efﬁcacy, in contrast to control volunteers and individuals vac-
inated with ChAd63-METRAP, who all developed malaria [39].
ChAdOx1.85A followed by intranasal or intradermal MVA85A
s a boost to BCG is a promising vaccination regimen that should
e investigated further for protective efﬁcacy in other preclinical
.tb infection models. A recent study using ChAdOx1.85A was very
mmunogenic in cattle [25]; it would therefore be interesting to
ee whether this can be improved further with MVA85A and more
mportantly whether this also correlates with protective efﬁcacy.
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